Drug Delivery Systems for Vitamin D Supplementation and Therapy

Główka, Eliza; Stasiak, Joanna; Lulek, Janina

doi:10.3390/pharmaceutics11070347

Cited by 72 publications

(47 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, vitamin D has also been incorporated—using calcitriol or some of its analogues as active components—in different drug delivery systems for food fortification or therapeutic applications [ 452 , 453 , 454 ]. To the best of our knowledge, these micro/nano-formulations have not been tested in NF1 patients; so this strategy can be attempted in the next future to improve NF1 patient management and their life quality.…”

Section: Vitamin D and Neurofibromatosismentioning

confidence: 99%

Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design

Riccardi

Perrone

Napolitano

et al. 2020

Cancers

View full text Add to dashboard Cite

Vitamin D is a fat-soluble steroid hormone playing a pivotal role in calcium and phosphate homeostasis as well as in bone health. Vitamin D levels are not exclusively dependent on food intake. Indeed, the endogenous production—occurring in the skin and dependent on sun exposure—contributes to the majority amount of vitamin D present in the body. Since vitamin D receptors (VDRs) are ubiquitous and drive the expression of hundreds of genes, the interest in vitamin D has tremendously grown and its role in different diseases has been extensively studied. Several investigations indicated that vitamin D action extends far beyond bone health and calcium metabolism, showing broad effects on a variety of critical illnesses, including cancer, infections, cardiovascular and autoimmune diseases. Epidemiological studies indicated that low circulating vitamin D levels inversely correlate with cutaneous manifestations and bone abnormalities, clinical hallmarks of neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant tumour predisposition syndrome causing significant pain and morbidity, for which limited treatment options are available. In this context, vitamin D or its analogues have been used to treat both skin and bone lesions in NF1 patients, alone or combined with other therapeutic agents. Here we provide an overview of vitamin D, its characteristic nutritional properties relevant for health benefits and its role in NF1 disorder. We focus on preclinical and clinical studies that demonstrated the clinical correlation between vitamin D status and NF1 disease, thus providing important insights into disease pathogenesis and new opportunities for targeted therapy.

show abstract

Section: Vitamin D and Neurofibromatosismentioning

confidence: 99%

Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design

Riccardi

Perrone

Napolitano

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…To this end, an orthotopic ovarian cancer mouse model would be the most suitable to evaluate the anti-metastasis activity of calcitriol [43,44]. In addition, to reach a higher drug concentration in the tumor site, drug delivery systems, such as nanoparticles or micelle, could be applied to improve the solubility of calcitriol and delivery to the tumors [45,46].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2

Wang

Zhou

Guo

2020

IJMS

View full text Add to dashboard Cite

Ovarian cancer is the most deadly gynecologic cancer among women worldwide. Poor response to current treatment makes it necessary to discover new diagnostic biomarkers to detect the cancer early and develop new and effective prevention strategies. Calcitriol, the active metabolite of vitamin D, protects against multiple cancers through unelucidated mechanisms. The oncogenic long non-coding RNA (lncRNA) CCAT2 (colon cancer associated transcript 2) is overexpressed in ovarian cancer. Here, we foundd that calcitriol inhibited CCAT2 expression in ovarian cancer cell lines. Treatment with calcitriol inhibited ovarian cancer cell proliferation, migration, and invasion. As a result of CCAT2 inhibition, calcitriol decreased the binding of transcription factor TCF7L2 (TCF4) to the MYC promoter, resulting in the repression of c-Myc protein expression. Our results suggest a novel anti-cancer mechanism of vitamin D by targeting CCAT2 in ovarian cancer. The findings may help develop vitamin D as a practical and inexpensive nutraceutical for ovarian cancer prevention.

show abstract

“…Microparticles are common oral delivery systems in addition to nanoparticles, and offer the means to improve the bioavailability of pharmaceuticals through the control over shape, size, geometry, and functional characteristics of the particle [78][79][80][81]. During the past few decades, microparticle technology has been extensively applied for various applications in therapeutic and pharmaceutical fields, such as the delivery of anti-inflammatories [82,83], antibiotics [84,85], chemotherapeutics [86,87], proteins [88], and vitamins [89,90]. Microparticle sizes range from 1 to 1000 μm and they exist in various structures [91].…”

Section: Micro and Nanoscale Carrier Typesmentioning

confidence: 99%

Micro and nanoscale technologies in oral drug delivery

Ahadian

Finbloom

Mofidfar

et al. 2020

Advanced Drug Delivery Reviews

166

View full text Add to dashboard Cite

Micro and nanocarriers Micro and nanoscale technologies Oral drug delivery Tissue models Oral administration is a pillar of the pharmaceutical industry and yet it remains challenging to administer hydrophilic therapeutics by the oral route. Smart and controlled oral drug delivery could bypass the physiological barriers that limit the oral delivery of these therapeutics. Micro-and nanoscale technologies, with an unprecedented ability to create, control, and measure micro-or nanoenvironments, have found tremendous applications in biology and medicine. In particular, significant advances have been made in using these technologies for oral drug delivery. In this review, we briefly describe biological barriers to oral drug delivery and micro and nanoscale fabrication technologies. Micro and nanoscale drug carriers fabricated using these technologies, including bioadhesives, microparticles, micropatches, and nanoparticles, are described. Other applications of micro and nanoscale technologies are discussed, including fabrication of devices and tissue engineering models to precisely control or assess oral drug delivery in vivo and in vitro, respectively. Strategies to advance translation of micro and nanotechnologies into clinical trials for oral drug delivery are mentioned. Finally, challenges and future prospects on further integration of micro and nanoscale technologies with oral drug delivery systems are highlighted.

show abstract

Drug Delivery Systems for Vitamin D Supplementation and Therapy

Cited by 72 publications

References 84 publications

Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design

Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design

Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2

Micro and nanoscale technologies in oral drug delivery

Contact Info

Product

Resources

About